AURKB and non-small cell lung carcinoma: Silencing of AURKB validated this concept, which resulted in a marked increased resistance to paclitaxel, confirming the effect that reduced AURKB expression modulates insensitivity to taxane in human lung cancer cells and, thus, may serve as predictive parameter to taxane response in NSCLC.